Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that their new drug application for Sacituzumab Tirumotecan (sac-TMT) has been accepted by China’s National Medical Products Administration, following positive results in a pivotal study for treating non-small cell lung cancer. The drug, which has shown significant improvements in treatment outcomes over docetaxel, is also set for a priority review. Investors are cautioned as the drug’s development and commercialization are not guaranteed.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.